Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.49 |
| ▸ | TYK2 | P29597 | 8/20 | 0.49 |
| ▸ | JAK1 | P23458 | 5/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848056 | 1.00 | JAK2 (0.49) | JAK2TYK2JAK1ROCK2ROCK1 | |
| SCHEMBL2848053 | 1.00 | JAK2 (0.49) | JAK2TYK2JAK1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL5956801 | 0.99 | JAK2 (0.48) | JAK2TYK2JAK1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL5956652 | 0.99 | JAK2 (0.48) | JAK2TYK2JAK1ROCK2ROCK1 | |
| SCHEMBL2856597 | 0.87 | TYK2 (0.44) | JAK2TYK2JAK1ROCK2ROCK1 | |
| SCHEMBL4443812 | 0.87 | TYK2 (0.44) | JAK2TYK2JAK1ROCK2ROCK1 | |
| SCHEMBL2856600 | 0.87 | TYK2 (0.44) | JAK2TYK2JAK1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL5956945 | 0.86 | TYK2 (0.43) | JAK2TYK2JAK1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL5956776 | 0.86 | TYK2 (0.43) | JAK2TYK2JAK1ROCK2ROCK1 | |
| SCHEMBL4441648 | 0.84 | KCNMA1 (0.49) | JAK2TYK2CYP3A4MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | JAK2 585/4885TYK2 354/4885JAK1 490/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | JAK2 460/4885TYK2 1877/4885JAK1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.